Trump Administration Pushes for Tariffs on Pharmaceuticals and Semiconductors Over National Security Concerns

The Trump administration has launched investigations into U.S. imports of pharmaceuticals and semiconductors, signaling the potential for new tariffs on both sectors. Citing national security concerns, the administration argues that the U.S. has become overly reliant on foreign suppliers for essential goods like medicines and semiconductor chips.

These investigations, initiated under Section 232 of the Trade Expansion Act, aim to assess whether the heavy dependence on foreign production, particularly from countries like Taiwan, South Korea, India, and China, poses a threat to U.S. security. If the probes result in a positive finding, tariffs ranging from 10% to 25% could be imposed on these critical imports.

The U.S. Department of Commerce will now evaluate the potential risks of this dependency, including the impact on national defense and the economy. Public comments on the investigations will be accepted for 21 days, with the probes expected to conclude within 270 days.

While some industry groups, especially in the pharmaceutical sector, have expressed concerns that such tariffs could lead to shortages and higher prices, the Trump administration remains focused on strengthening domestic manufacturing and reducing foreign dependence.